Clinical Trials Using Anti-HER2-vc0101 ADC PF-06804103

Clinical trials are research studies that involve people. The clinical trials on this list are studying Anti-HER2-vc0101 ADC PF-06804103. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trial 1 of 1
  • PF-06804103 Dose Escalation in HER2 Positive Solid Tumors

    The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of PF-06804103 in patients with HER2 positive solid tumors. The study will expand to look at the selected dose in patients with breast cancer, gastric cancer and non-small cell lung cancer
    Location: 4 locations